managing antiretroviral therapy in treatment-experienced patients: first regimen failure matec...
TRANSCRIPT
![Page 1: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/1.jpg)
Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure
MATECCatherine Creticos, M.D.
Medical Director
![Page 2: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/2.jpg)
Objectives
Explain possible causes of drug failureDescribe tests used to assess viral resistance
Explain how to use resistance test results to select an effective new regimen
Discuss strategies for managing patients with limited treatment options
![Page 3: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/3.jpg)
Case Study 1
A.D. is a 51 yo male HIV+ since 1989. He started Combivir in 1993, and his viral load remained undetectable until June 2006, with CD4 in the 400-600 range. Since June 2006, his viral load on 2 occasions has been 24,500 and 37,800 respectively. His most recent CD4 count was 378 cells.
![Page 4: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/4.jpg)
First Antiretroviral Treatment Failure
Assessment What are possible causes of increased viral
load? Is intervention necessary at this point?
Why / Why not? What intervention(s)?
![Page 5: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/5.jpg)
Reasons for First Antiretroviral Therapy Regimen Failure
Viral load , but patient not failing regimen recent infection (eg, HSV outbreak, bacterial
infection, acute hepatitis) recent vaccination
Poor adherence – regimen may still be salvagable
Poor absorption (unboosted PIs) Drug-drug interactions (eg, PPIs and
atazanavir) Incompletely suppressive regimen (eg, dual
nucleoside)
![Page 6: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/6.jpg)
First Antiretroviral Failure: Interventions
Review adherence – last month, last few days Probe for recent events, problems (eg, recent
infection or other issues such as running out of medication or not taking medication on a trip)
Repeat viral load (can be done at same time as resistance assay)
Resistance assay – purpose is to identify specific drug resistance that has led to failure and to assist in the selection of the next regimen
![Page 7: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/7.jpg)
Rationale for HIV Resistance Testing
Drug resistance at start of ART is predictor of virologic response
Several prospective studies support use of resistance testing to improve response to ART
Preliminary economic studies suggest resistance testing cost-effective after first HAART failure
Prevalence of resistance in acute/recent HIV infection 10%-26% in recent studies
![Page 8: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/8.jpg)
Current Recommendations forUse of Resistance Testing (DHHS)
Recommended for selection of active drugs when changing therapy if viral suppression is suboptimal w/initial regimen
Recommended for pregnant women initiating therapy or with incomplete virologic suppression
May be useful in cases of acute infection or infection within the last 1-2 years
Not yet recommended at initiation of therapy in all treatment-naïve individuals until more information available on prevalence; however in areas of high prevalence, resistance testing may be useful
Both phenotyping and genotyping may be useful in patients with complex prior treatment history
![Page 9: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/9.jpg)
Evolution of Drug Resistance
Causes of high genetic variability of HIV: DNA copy of RNA genome for replication Lack of proofreading by RT during replication Every possible point mutation occurs ~1,000-10,000 times a
day; double mutants common Genetic recombination between different viruses in the same
cell
Acquisition of resistance during tx depends on: Size and heterogeneity of viral population Extent of replication during drug therapy Ease of acquisition of particular mutation Effect of mutation on drug susceptibility and viral fitness
![Page 10: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/10.jpg)
How drug resistance arises. Richman, DD. Scientific American , July 1998
How Drug Resistance Arises
![Page 11: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/11.jpg)
Resistance Testing: Definitions
Mutation (molecular definition): change in nucleic acid sequence compared with consensus or wild-type virus
point mutation: AAA GAC AGT=>AAA AAC AGC insertion: AAA AAC AGT=> AAA AAC AGT AGT deletion: AAA AAC AGT=> AAA…AGT
Drug resistant mutation: change in amino acid sequence (vs. reference strain) that affects susceptibility to a drug
Major, primary: can solely affect susceptibility Minor, secondary, accessory: contributes to reduced susceptibility
Polymorphism: a naturally occurring change in amino acid sequence not shown to directly impact drug susceptibility
![Page 12: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/12.jpg)
Mutational Nomenclature
Wild-type amino acid G48V Mutant amino acid
Codon Position
Mixtures are indicated by a slash K103K/N indicates mixture of wild-type and
mutant T215D/Y/F indicates mixture of 3 mutants
![Page 13: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/13.jpg)
Resistance Assays: Phenotype and Genotype
Phenotype: Direct assay: measures ability of the virus to
grow in various concentrations of antiretroviral drugs.
Genotype: Indirect assay: detects drug resistance
mutations that are present in the relevant viral genes.
Both assays focus on the reverse transcriptase (RT) and protease (PR) genes of the virus
![Page 14: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/14.jpg)
Phenotyping: Advantages
Provides resistance information on each drug regardless of the presence of multiple mutations
Interpretation may be more intuitive than for genotype assay
Very useful in patients with complex drug history and complicated mutation profile
Very useful for deciphering cross-resistance May be more useful than genotyping for
new drugs until appropriate mutations are established by clinical data
![Page 15: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/15.jpg)
Phenotyping: Disadvantages
If drug resistant population is minor, the phenotypic effect may not be detected
Viral load needs to 1000 copies/ml Very expensive and time-consuming Consensus on drug-resistance cut-off values are not
yet fully determined - drugs to which a patient is actually still sensitive may be unnecessarily eliminated
initial cut-offs were based on assay variability on repeated testing of known sample
later cut-offs were based on natural variability of wild-type viruses from patients
current cut-offs are being developed based on outcome data from clinical trials
![Page 16: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/16.jpg)
Antivirogramphenotype
![Page 17: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/17.jpg)
PhenoSense HIV Report
![Page 18: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/18.jpg)
Sequence-based Genotyping Assays
HIV circulating in patient’s plasma is isolated; RT and PR genes are copied, amplified & sequenced.
The test sequence is compared to a reference HIV strain and all changes (mutations) are noted.
Software compares changes found to a list of the mutations known to be associated with resistance.
A report documents any mutations and (optimally) the ARV drugs to which the virus is sensitive or resistant based on the presence or absence of particular mutations.
![Page 19: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/19.jpg)
Available Genotypes
Company Product Name Turnaround Time
RNA Sensitivity
Mixture Sensitivity
Monogram Biosciences GeneSeq™ HIV 14 Days ≥ 500 copies 10%
LabCorp GenoSureGenoSure Plus 10-28 Days ≥ 1000 copies Not available
Quest Genotype (ABI kit)Vircotype 7-14 Days ≥ 600 copies 25%
ARUP ViroSeq (ABI kit) Variable ≥ 500 copies 10%Specialty Labs GenotypR Plus 7 Days ≥ 1000 copies Not available
Virco GenchecVirtual Phenotype 14 Days ≥ 1000 copies 10-20%
Bayer TRU-Gene (kit) 3-14 Days ≥ 1000 copies Not availableABI ViroSeq (kit) Variable ≥ 500 copies 20%
![Page 20: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/20.jpg)
Genotyping: Advantages
Identification of all nucleotides, amino acid differences, deletions & insertions
Genotyping has the ability to detect resistant virus that constitutes only a small proportion (~ 20%) of the viral population.
This can provide “predictive” early warning of resistance before full resistance develops
Faster and less expensive than phenotype assay
![Page 21: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/21.jpg)
Genotyping: Disadvantages
Reports may be difficult to interpret unless clinician is very experienced
Labs use different software to predict resistance - a consensus on which mutations are important is needed
There is a lot of variation in the quality of the “product” from different labs, especially in the ability to detect minority species in the population
Significance of many mutations still poorly understood Lack of understanding of the significance of
combinations of mutations Viral load needs to 1000 copies/ml
![Page 22: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/22.jpg)
Phenotype/Genotype Discordance:
Interpretation Discordance interpretation is incorrect (especially new
drugs) data base is incomplete or lacking
Test Result Discordance PT sensitive but GT resistant mixtures transitional mutations antagonistic mutational interactions
![Page 23: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/23.jpg)
Genotype-Phenotype Discordance
Observed differences between phenotype and genotype are not uncommon
Reasons for genotype-phenotype discordance use of inaccurate genotype interpretation
algorithms (not accounting for novel or unknown mutations, or for unrecognized effects of mutations)
Presence of mixtures of wild-type and resistant strains
Variability in phenotypic susceptibility with specific mutations
![Page 24: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/24.jpg)
Virtual Phenotype
Determines genotype of test strainComputer algorithm matches genotype to strains that have been previously phenotyped
Presents expected phenotype based on the average phenotype of matching isolates
![Page 25: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/25.jpg)
Virtual Phenotype: Pros and Cons
Pros Inexpensive, quick way
to generate phenotypic information
Clinical studies show good correlation between virtual and real PT and equal efficacy in predicting viral suppression
Cons number of matches
may be low “union” of limitations of
GT and PT techniques clinical studies do not
demonstrate benefit of virtual PT added to GT and expert advice
![Page 26: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/26.jpg)
NRTIs
Major Mutations
![Page 27: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/27.jpg)
NRTIs:Special Considerations
Require triphosphorylation, complicates in vitro assessment & PT testing discordance b/w in vitro and in vivo potency
NEMs (TAMs) selected primarily in patients treated with AZT or D4T; 10% of patients on DDI monotherapy; rarely during ABC monotherapy
Some NRTI mutations hypersensitize HIV to NNRTIs K65R confers intermediate resistance to DDI, ABC, TDF,
3TC. Recent study of ABC/3TC/TDF led to high failure rate Q151M is a 2-base pair change that causes intermediate
resistance to AZT, DDI, D4T, and ABC TDF efficacy reduced by 3 or more TAMs, especially in
presence of M41L or L210W
![Page 28: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/28.jpg)
Mutational Interactions: M184V
M184V- causes high-level 3TC resistance and low-level resistance to ddI, ddC, ABC
M184V reverses T215Y-mediated AZT resistance
Resensitization clinically significant; slows AZT resistance in patients on AZT/3TC
M184V appears to reverse effect of NEMs on resistance to d4T, TDF
![Page 29: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/29.jpg)
NNRTIs
Major Mutations
![Page 30: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/30.jpg)
NNRTI Mutations:Special Consideration
Y181C/I causes high-level resistance to NVP and DLV, but low-level resistance to EFV. However, isolates only transiently respond to EFV
Y181C and L100I hypersensitize HIV to AZT G190A/S are resistant to NVP and EFV but
hypersensitive to DLV
![Page 31: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/31.jpg)
PIs
Major Mutations
![Page 32: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/32.jpg)
PIs:Special Considerations
Cross-resistance problematic; in one study of over 6,000 isolates, 59%-80% of isolates with a 10-fold decrease in susceptibility to one PI also had a 10-fold decrease to at least one other
For LPV/r, at least 4 of 11 mutations may be needed for significant resistance
NFV and ATV when used as first PI may select for mutations with little cross-resistance: NFV – D30N ATV – I50L
![Page 33: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/33.jpg)
Stanford HIV Database
http://hivdb.stanford.eduCan insert mutations and receive an assessment of resistance and a discussion of significance of the mutations
![Page 34: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/34.jpg)
![Page 35: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/35.jpg)
![Page 36: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/36.jpg)
![Page 37: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/37.jpg)
Case Study 1:A.D.
Genotype shows:M184V, D67N, K70K/R, and K219K/Q
Reference lab predicted resistance to AZT, ABC, 3TC, FTC, d4T;
No resistance to DDI, TDF, all NNRTIs & PIs
Stanford database interpretationNucleoside RTI:
3TC: High-level resistance ABC: Low-level resistance AZT: Intermediate resistance D4T: Low-level resistance DDI: Potential low-level
resistance FTC: High-level resistance TDF: Susceptible
Non-Nucleoside RTI DLV: Susceptible EFV: Susceptible NVP: Susceptible
![Page 38: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/38.jpg)
Stanford Database Comments on Significance of Mutations
D67N contributes some degree of resistance the NRTIs except 3TC and FTC. It usually occurs with mutations at positions 70 or 215. D67E/G occur in heavily treated patients and probably have a similar effect as D67N.
K70R causes low-level AZT and probably D4T resistance but appears to have little effect on the other NRTIs. K70E reduces TDF susceptibility. K70G/N are rare variants of unknown significance.
![Page 39: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/39.jpg)
Stanford Database Comments on Significance of Mutations
M184V/I cause high-level resistance to 3TC and FTC, and low-level in vitro resistance to DDI and ABC. However, it has not been shown to limit the effectiveness of DDI and it has only been shown to limit the effectiveness of ABC when it occurs in combination with multiple TAMs. M184V partially reverses T215Y-mediated resistance to AZT, TDF, and D4T.
K219Q/E increase AZT and probably D4T resistance when present with K70R or T215Y/F but may not have any effect on the remaining NRTIs. K219N/R occur commonly in heavily NRTI-treated patients.
M184V partially reverses AZT, D4T, and TDF resistance caused by other TAMs.
![Page 40: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/40.jpg)
Case Study 1:Treatment Selection and Response
Started Atripla (TDF/3TC/EFV) and Ziagen
What are other reasonable treatment choices?
6 weeks after initiating therapy, patient’s viral load is undetectable
Continued close f/u is warranted
![Page 41: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/41.jpg)
Case Study 2
K.L. is a 36 yo male with diabetes and HIV. He has been treated with Combivir and Sustiva as well as glipizide. He presents with decreased vision bilaterally, R>>L eye. An ophtholmologic exam reveals acute retinal necrosis and w/u shows an RPR 1:512. He is treated for syphilitic retinitis with significant improvement in his vision. His viral load = 38,900 and CD4 = 285. He admits to poor adherence over past 2 months. A GT is performed and shows K103N & M184V mutations.
![Page 42: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/42.jpg)
Clinical Decisions and Questions
What antiretroviral combinations would be appropriate to consider?
What type of follow-up should be done if therapy is changed?
What additional concerns need to be addressed?
![Page 43: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/43.jpg)
Case Study 2Treatment Selection and Response
His regimen is changed to: ATV/RTV/TDF/3TC/ZDV.
After 3 months, the viral load is undetectable and CD4 is 354
![Page 44: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/44.jpg)
Case Study 3
K.C. is a 41 y.o. female with a history of former IVDU and HCV/HIV co-infection. She was treated initially with Viracept and Combivir. She has a long history of non-compliance and her viral load was never undetectable. She was changed to Combivir and Kaletra, but her viral load remained high at 53,000. A GT is done and shows no resistance mutations. A discussion with the patient reveals very poor adherence due to GI side effects and difficulty remembering her pills.
![Page 45: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/45.jpg)
Clinical Decisions and Questions
What is the meaning of the resistance assay and is it believable?
Is it appropriate to start a new antiretroviral regimen in this patient?
If so, what antiretroviral drugs would be appropriate?
What other concerns should be addressed?
What follow-up should be done?
![Page 46: Managing Antiretroviral Therapy in Treatment-Experienced Patients: First Regimen Failure MATEC Catherine Creticos, M.D. Medical Director](https://reader033.vdocuments.net/reader033/viewer/2022050714/56649e5e5503460f94b57af3/html5/thumbnails/46.jpg)
Case Study 3:Treatment Selection and Response
She is changed to ATV/RTV/TDF/ETV and these are given daily with her methadone.
Patient’s viral load after 3 months (and subsequently for the next year) is undetectable